



**HAL**  
open science

## Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: Importance of hyaluronan for the mitogenic response of PDGF-BB

Lingli Li, Trias Asteriou, Berit Bernert, Carl-Henrik Heldin, Paraskevi Heldin

### ► To cite this version:

Lingli Li, Trias Asteriou, Berit Bernert, Carl-Henrik Heldin, Paraskevi Heldin. Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: Importance of hyaluronan for the mitogenic response of PDGF-BB. *Biochemical Journal*, 2007, 404 (2), pp.327-336. 10.1042/BJ20061757 . hal-00478704

**HAL Id: hal-00478704**

**<https://hal.science/hal-00478704>**

Submitted on 30 Apr 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: Importance of hyaluronan for the mitogenic response of PDGF-BB

Lingli LI<sup>1</sup>, Trias ASTERIOU<sup>1</sup>, Berit BERNERT<sup>1</sup>, Carl-Henrik HELDIN<sup>1</sup> and Paraskevi HELDIN<sup>1,2\*</sup>

<sup>1</sup>Ludwig Institute for Cancer Research, Uppsala University, Biomedical Center, Box 595, S-751 24 Uppsala, Sweden <sup>2</sup>Dept. of Medical Biochemistry and Microbiology, Uppsala University, Biomedical Center, Box 582, S-751 23 Uppsala, Sweden

\*To whom correspondence should be addressed: Phone, 00 46 18 471 4261; Fax, 00 46 18 16 0420; E-mail, [Paraskevi.Heldin@imbim.uu.se](mailto:Paraskevi.Heldin@imbim.uu.se)

---

The glycosaminoglycan hyaluronan is important in many tissue repair processes. We have investigated the synthesis of hyaluronan in a panel of cell lines of fibroblastic and epithelial origin in response to platelet-derived growth factor (PDGF)-BB and other growth factors. Human dermal fibroblasts exhibited the highest hyaluronan synthesizing activity in response to PDGF-BB. Analysis of hyaluronan synthase (*HAS*) and hyaluronidase (*HYAL*) mRNA expression showed that PDGF-BB treatment induced a 3-fold increase in the already high level of *HAS2* mRNA, and increases in *HAS1* and *HYAL1* mRNA, whereas the levels of *HAS3* and *HYAL2* mRNA were not affected. Furthermore, PDGF-BB also increased the amount and activity of *HAS2* protein, but not of *HYAL1* and *HYAL2* proteins. Using inhibitors for MEK1/2 (U0126) and for PI3 kinase (LY294002), as well as the SN50 inhibitor, that prevents translocation of the active NFκB to the nucleus, we observed a complete inhibition of both *HAS2* transcriptional activity and hyaluronan synthesis, whereas inhibitors of other signaling pathways were without any significant effect. Transforming growth factor-β1 (TGF-β1) did not increase the activity of hyaluronan synthesis in dermal fibroblasts, but increased the activity of *HYAL*s. Importantly, inhibition of hyaluronan binding to its receptor CD44 by the monoclonal antibody Hermes-1, inhibited PDGF-BB-stimulated [<sup>3</sup>H]thymidine incorporation of dermal fibroblasts. We conclude that the Erk MAP kinase and PI3 kinase signaling pathways are necessary for the regulation of hyaluronan synthesis by PDGF-BB, and that prevention of its binding to CD44 inhibits PDGF-BB-induced cell growth.

---

Running title: PDGF-BB-induced hyaluronan synthesis and its importance for cell proliferation.

## INTRODUCTION

Hyaluronan is a glycosaminoglycan consisting of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine. It is found in particular in soft connective tissues and is the major component in synovial joint fluid, vitreous body and skin, both in dermis and epidermis, contributing both to the structural and functional integrity [1, 2]. Hyaluronan is synthesized by three hyaluronan synthesizing enzymes (HAS1, 2 and 3) located at the plasma membrane, and the newly synthesized molecule is extruded into the extracellular space while the synthesis is in progress [3-5]. Among the three HAS isoforms, the HAS2 isoform is required for embryonic development since mice deficient in the *HAS2* gene die at embryonic day E 9.5; in contrast, mice deficient in *HAS1* and *HAS3* genes are viable [6].

Hyaluronan accumulation is a prominent feature of rapidly remodeling tissues. For example, during embryonic development, hyaluronan production facilitates the migration of differentiating cells and stimulates their transformation to a mesenchymal phenotype [6]. Furthermore, hyaluronan is involved in the skin wound-healing process from the early inflammatory process to re-epithelization and remodeling [7], and is involved in scarless fetal healing most likely by reducing collagen deposition [7, 8]. In addition, hyaluronan overproduction promotes tumorigenesis in several tumor types, whereas suppression of hyaluronan production decreases tumorigenicity [9, 10]. Accumulation of hyaluronan synthesis can arise from both increased synthesis and decreased degradation. Hyaluronan is degraded by the action of hyaluronidases (HYALs), including HYAL1, HYAL2 and PH-20 that have demonstrated bona fide hyaluronidase activity [11]. Hyaluronan degradation occurs locally in several tissues, for example in dermis where hyaluronidase activities have been demonstrated [12, 13], however, the mechanisms of hyaluronan metabolism in the connective tissues under physiological and inflammatory conditions are still largely unknown.

Hyaluronan interacts with several cell surface receptors, such as CD44, RHAMM and LYVE-1, and extracellular components, such as versican and aggrecan [14, 15]; through its complex interactions, hyaluronan affects a variety of physiological cellular events, such as cell proliferation, differentiation and migration. Because of its hygroscopic and viscoelastic

properties, hyaluronan also affects cellular behavior via remodeling of the macro- and microenvironments around cells [16-19].

Growth factors play central roles during both normal and pathological conditions, including embryogenesis, wound healing and tumor invasion, i.e. biological processes characterized by increased amounts of hyaluronan. Platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1), which are produced by both normal and transformed cells, are powerful stimulators of hyaluronan production by certain mesenchymal cells [16, 20-22]. PDGF-BB mediates its cellular effects through activation of  $\alpha$ - and  $\beta$ -tyrosine kinase receptors. Ligand binding causes receptor dimerization, leading to autophosphorylation of specific tyrosine residues in the intracellular parts of the receptors. This creates docking sites for SH2 domain containing signaling molecules, whereby several signaling pathways are activated [23]. PDGF receptors can act synergistically with  $\alpha_v\beta_3$  integrin to promote tumor cell tissue infiltration [24]. However, recent studies in our laboratory on primary cultures of human dermal fibroblasts, revealed that high concentrations of exogenous hyaluronan negatively affects PDGF  $\beta$ -receptor activation and cell migration in a CD44-dependent manner [25]. In normal fibroblast cultures, the intracellular signaling pathways that regulate the turnover of hyaluronan in response to external stimuli have not yet been clarified. Here, we demonstrate that the effect of PDGF-BB on hyaluronan synthesis in human dermal fibroblast cultures is due to induction of HAS2. In contrast, TGF- $\beta$ 1 has no effect on hyaluronan synthesis but enhances hyaluronan degradation by stimulation of hyaluronidase activity. Moreover, we show that the Ras-Erk MAP kinase and PI3 kinase pathways are important for PDGF-BB-stimulated hyaluronan production in these cells, and that hyaluronan binding to its receptor CD44 is important for PDGF-BB-induced cell growth.

## **MATERIALS AND METHODS**

### **Cell cultures**

Biopsies were taken, after approval, from patients undergoing breast reduction surgery at Department of Plastic Surgery of the University Hospital, Uppsala, Sweden essentially as described previously [25]. Briefly, the biopsies were transported to the laboratory in chilled phosphate buffered saline without  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  (PBS), supplemented with antibiotics (100 IU penicillin/ml and 100  $\mu\text{g}$  streptomycin/ml; Veterinary Institute, Uppsala, Sweden), washed with 70% ethanol, followed by PBS washing, and minced to 1-2  $\text{mm}^3$  pieces with a razor blade. After an overnight incubation in 25 mg dispase/10 ml Dulbecco's modified Eagles

medium (grade II, 0.5 U/ml, Boehringer Mannheim / DMEM) at 4°C, dermis and epidermis were separated, using a fine forceps. Fibroblasts from the dermal sheet explants were then cultured in complete medium (DMEM containing 10% fetal bovine serum (FBS, Biowest and antibiotics), and used between passages 6 to 10 for all experiments. Normal human epidermal keratinocytes were released from the epidermal sheets by incubation with 4 mg/ml trypsin and 4 mg/ml glucose in 0.02% EDTA at 37°C for 1 h. After gentle pipetting, 10% FBS was added to stop the enzymatic activity, whereafter keratinocytes were washed and collected by centrifugation. Keratinocytes (60-70% confluence, passage three) were grown in EpiLife™ keratinocyte medium (Sigma, # E0151), containing Keratinocyte Medium Supplement bovine pituitary extract-free and 10% FBS.

DMEM supplemented with 10% FBS was also used in the culture of HEK 293 cells, Cos-1 cells, 3T3 cells, human foreskin fibroblasts (AG1518, AG1523; Human Mutant Cell Repository, Camden, NJ, USA), mouse embryonal fibroblasts (MEFs), the mouse epithelial cell line NMuMG (kindly provided by Anita Moren, Ludwig Institute for Cancer Research, Uppsala, Sweden; medium contained also 10 µg/ml insulin), and fibroblasts derived from keloid-like dermal scars (generously provided by Bengt Gerdin, Akademiska hospital, Uppsala, Sweden).

### **Polyclonal antibodies against human HAS2 and HYAL2, as well as peptide synthesis**

To raise polyclonal antibodies against HAS2 and HYAL2 we chose the peptide CGRRKKGQYDMVLD that corresponds to amino acid residues 537-549 at the C-terminal domain of HAS2 and is conserved in both human and mouse HAS2 [26, 27], and the peptide PGHAPGEPQLRPVG that corresponds to amino acid residues 398-411 at the C-terminal domain of human HYAL2 [28]. The peptides were synthesized using the N-(9-fluorenyl) methoxycarbonyl strategy which resulted in a carboxy-terminal amidated domain to facilitate subsequent coupling to Keyhole Limpet Hemocyanin for rabbit immunization. Furthermore, a cysteine residue was added to PGH peptide at the C-terminal domain, in order to facilitate a subsequent coupling to a SulfoLink resin (<http://www.jbc.org/cgi/content/full/278/41//cgi/redirect-inline?ad=Pierce> Pierce), and used to affinity purify the antibodies. The peptides were purified by reversed-phase high pressure liquid chromatography and rabbits were immunized (service by EUROGENETEC, Belgium). The antisera were used directly or after purification on a HiTrap Protein G HP column (Amersham Biosciences), according to the instructions of the manufacturer.

### Determination of hyaluronan synthesis

Cells ( $3 \times 10^4$  cells/well in 12 well plates, or as indicated) were incubated in complete medium for 24 h, whereafter the medium was replaced with DMEM containing 0.1% FBS (starvation medium). Then, the quiescent cells received fresh starvation medium and were stimulated for an additional 24 h with PDGF-BB, other growth factors or growth factor combinations, or 10% FBS. In parallel, non-stimulated and PDGF-BB-stimulated human dermal fibroblasts were incubated with the following inhibitors of downstream signaling molecules: the MEK1/2 inhibitor U0126 (used at a concentration of 10  $\mu$ M, Calbiochem #662005), PI3-kinase inhibitor LY294002 (20  $\mu$ M, Calbiochem #440202), Src inhibitor SU6656 (1.5  $\mu$ M, Calbiochem #572635), p38 inhibitor SB203580 (10  $\mu$ M, Calbiochem #559389) and NF $\kappa$ B SN50 inhibitor peptide (16  $\mu$ M, Calbiochem #481480), as well as the NF $\kappa$ B SN50M inactive control peptide (16  $\mu$ M, Calbiochem #481486).

The hyaluronan content in 24 h conditioned media was quantified, essentially as described previously [9]. This assay is based on the highly specific and irreversible capture of hyaluronan molecules in the samples with immobilized hyaluronan binding protein (HABP) domain of aggrecan, from bovine cartilage [29]; proteins that bind hyaluronan with such high affinity are not present in the fibroblast cultures [30]. The HABP-hyaluronan complexes are then detected by biotinylated-HABP (b-HABP) and streptavidin biotinylated horseradish peroxidase (HRP) followed by a chromogenic reaction. The assay was carried out on MaxiSorb 96-well Nunc-Immuno Plates (Nunc #439454) pre-coated overnight with 1  $\mu$ g HABP/ml in 50 mM carbonate buffer, pH 9.5. After three washes in PBS containing 0.5% Tween 20, and blocking in PBS supplemented with 1% BSA, the hyaluronan standards (0-100 ng/ml, Mw 0.5 -  $1.5 \times 10^6$ , Genzyme Hylumed) and samples, at appropriate dilutions in blocking solution, were added and the plates were incubated for 1 h at 37°C. Following washing, 100  $\mu$ l of biotinylated HABP (b-HABP; 1  $\mu$ g/ml) was added and samples were incubated for 1 h. Then, after removing excess b-HABP, the b-HABP bound to the hyaluronan trapped by the HABP-coated plates was detected by incubation for 1 h with streptavidin biotinylated HRP (Amersham Bioscience #RNP1015V), followed by the addition of 100  $\mu$ l 3,3',5,5' tetramethylbenzidine substrate solution (Sigma #T4444) for 15 minutes. Then, 50  $\mu$ l of 2 M H<sub>2</sub>SO<sub>4</sub> was added and the absorbance at 450 nm was measured. The hyaluronan content in the conditioned media was calculated by comparing with a standard curve made from known concentrations of hyaluronan. It is unlikely that hyaluronan binding

proteins secreted into the conditioned medium affected the result, since treatment of the conditioned medium with proteases before the assay, had no effect (unpublished data).

### **Detection of HYAL activity in human dermal fibroblast cultures**

The activity of HYALs in fibroblast conditioned media and cell-layers harvested after 6 h from unstimulated and PDGF-BB- or TGF- $\beta$ -stimulated cells was quantitatively estimated using a microtiter-based assay essentially as described by Frost and Stern [31]. In this assay biotinylated hyaluronan (substrate) is covalently coupled to Covalink-NH 96-well microtiter plates. After removal of the coupling solution and three washings with PBS supplemented with 2 M NaCl and 50 mM MgSO<sub>4</sub>, the plates were equilibrated with assay buffer (0.1 M formate, pH 3.7, 0.15 NaCl and 1% Triton X-100).

Conditioned medium from each sample supplemented with 1  $\mu$ g/ml aprotinin was cleared by centrifugation, and dialyzed against 0.01 M formate, pH 3.7, 0.015 M NaCl containing aprotinin over-night at 4°C. Cell layers extracted for 30 min with 1 ml of ice-cold 0.01 M formate, pH 3.7, 0.015 M NaCl and 0.1% Triton X-100 containing DNase I (0.5 mg/ml), aprotinin (1  $\mu$ g/ml) and Pefabloc (0.5 mg/ml), were sheared through a 20 gauge needle and centrifuged at 10 000 x g for 15 min. Then, the samples were concentrated 10-fold and the protein content was measured by the BCA kit. Samples of conditioned media and of cell layers as well as *Streptomyces hyaluronidase* standards (1.0 to 1 x 10<sup>-6</sup> U/ml; Sigma-Aldrich) were diluted with the assay buffer at appropriate dilutions, and added in the Covalink plates with immobilized biotinylated hyaluronan. After 1 h of incubation, under shaking at 37°C, the reaction was stopped with 6 M Guanidinium-HCl followed by three washes with PBS supplemented with 2 M NaCl, 50 mM MgSO<sub>4</sub> and 0.05% Tween. Then, the residual coupled biotinylated-hyaluronan was detected with streptavidin biotinylated HRP reaction and the complexes were visualized as described above.

### **Immunoblotting**

Human dermal fibroblasts (4 x 10<sup>5</sup> cells in 10 cm dish) were cultured in DMEM containing 10% FBS for 24 hours. After incubation in starvation medium for 24 h, quiescent cells or cells stimulated with various concentrations of PDGF-BB (5 - 50 ng/ml) or TGF $\beta$  (2.5 and 5 ng/ml), were incubated in the absence or presence of 10  $\mu$ M U0126 or 20  $\mu$ M LY294002. At different time intervals after treatment, the medium was removed and cell layers were washed two times with ice-cold PBS followed by lysis in 50  $\mu$ l of ice-cold RIPA buffer (50 mM Hepes, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 1% NP-40, 0.1% SDS, 1% deoxycholate,

1 mM dithiothreitol) containing phosphatase and protease inhibitors (50 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 0.5 mg/ml pefabloc, 10 μM leupeptin, 2 mM pepstatin and 1 μg/ml aprotinin) and mixing at 4°C for 30 min. Cell lysates were scraped into microfuge tubes on ice, sheared by a 20 gauge needle, incubated an additional 30 min on ice and centrifuged at 14 000 x g for 15 min, at 4°C, in order to remove insoluble debris. The protein content in the supernatant was measured by BCA kit (Pierce). Then, samples (40 μg protein per well) were mixed with one volume of reducing sample buffer, denatured at 95°C for 3 min, cooled down for 15 min before addition of 20 mM iodoacetamide and separation on SDS-PAGE using 10% polyacrylamide gels, followed by transfer to nitrocellulose membranes (Amersham Biosciences, Uppsala, Sweden). Non-specific binding sites on the membrane were blocked with 5% defatted milk in Tris-buffered saline (TBS-T; 50 mM Tris HCl, pH 7.4, 200 mM NaCl, supplemented with 0.1% Tween-20), at room temperature for 1 h, followed by two washes in TBS-T. Then, the membranes were incubated either with phospho-p44/42 Erk MAP kinase (Thr202/Tyr204) rabbit monoclonal antibodies (p-Erk1/2; dilution 1:1000; Cell Signaling Technology #4377), phospho-Akt (Ser473) rabbit antiserum (p-Akt; dilution 1:1000; Cell Signaling Technology #9271), rat monoclonal antibody 17E9 against Hyal1 (2 μg/ml; kindly provided by Dr G. Frost, Sidney Kimmel Cancer Center, San Diego, USA), polyclonal HYAL2 antiserum (1:300 dilution), or rabbit anti-HAS2 IgG (5 μg/ml; HiTrap protein G HP purified HAS2 antiserum) in TBS-T buffer containing 1% BSA overnight at 4°C. The endogenous levels of Erk1/2 and Akt were detected by incubating the membranes with rabbit polyclonal anti-Erk1/2 antiserum (1:250 dilution; kindly provided by Charlotte Rorsman, Ludwig Institute for Cancer Research, Uppsala) and anti-Akt antiserum (1:1000 dilution; Cell-Signaling Technology #9272), respectively. After five washes with TBS-T, the membranes were incubated either with anti-rabbit horseradish peroxidase IgG (1:3000 diluted in 5% defatted milk in TBS-T) or with anti-rat horseradish peroxidase IgG (1:1000 diluted in 5% defatted milk in TBS-T). Immunoreactive bands were detected by enhanced chemiluminescence, stripped with Stripping buffer (Pierce, #21059) and re-blotted with antibodies, as specified.

### **Real-time PCR**

Total RNAs were obtained from human dermal fibroblast cultures (4 x 10<sup>5</sup> cells per 10 cm dish) incubated in starvation medium alone or in medium supplemented with PDGF-BB (50 ng/ml), U0126 (10 μM), LY294002 (20 μM), or combinations thereof, as well as 10% FBS. After 1, 4 and 24 h of treatment, the cells were washed twice with PBS and the total



RNAs were extracted by using RNAqueous<sup>TM</sup> - 4PCR Kit (Ambion #1914). Each of the total RNAs were further treated with DNase I, followed by DNase inactivation (Ambion #1914), in order to obtain DNA-free total RNA. The purity of the RNAs was verified by measurement of 260/280 nm OD values (ratio  $\geq 2.0$ ), and their integrity were determined by separation in a 1% agarose formaldehyde gel, followed by inspection under UV light. Then, each purified RNA (2  $\mu$ g RNA in 20  $\mu$ l of total reaction volume) was reverse-transcribed into the corresponding cDNA by SuperScript<sup>TM</sup> II RNase H<sup>-</sup> Reverse Transcriptase (Invitrogen #18064-014), followed by real-time PCR using qPCR<sup>TM</sup> Core kit for SYBR<sup>®</sup> Green I (Eurogentec # RT-SN73-05), according to the instruction of the manufacturer. The primers for the target genes (*HASI*, 2, 3 and *HYALI*, 2; final concentration of 300 nM) and reference gene *GAPDH* (final concentration 100 nM) were designed by Primer Express<sup>®</sup> Software v 2.0 (Applied Biosystems) and synthesized by Applied Biosystems (Table 1). Each reaction mixture, in addition to the specific primer, contained 1  $\mu$ l of cDNA from RT reactions, 3.5 mM MgCl<sub>2</sub>, 200  $\mu$ M dNTPs, SYBR<sup>®</sup> Green I (1/66 000) and Hot Goldstar enzyme (0.025 units / $\mu$ l); it was amplified for 40 cycles at an annealing temperature of 60°C using an ABI PRISM 7000 Sequence Detection System (SDS Software; Applied Biosystems). For each optimized assay, a relative standard curve was run which resulted in a linear plot of threshold values ( $C_T$ , which reflects the cycle number at which statistically significant amplicon numbers have been accumulated above the baseline) toward log input total RNA (0 - 100 ng); the slope values of each constructed standard curve were approximately equal (within 10% from the theoretical value of the slope which should not be lower than -3.3 [32]), indicating a similar amplification efficiency of each target. A dissociation curve analysis was performed to verify the presence of correct product at predicted melting temperatures and absence of primer dimers. Using Excel, the relative expression level of each target normalized to endogenous reference gene (*GAPDH*) and relative to a calibrator (sample exhibiting the lowest expression level, 1 x sample) was measured by using the comparative  $C_T$  method (Applied Biosystems, User Bulletin #2).

### **Proliferation assay**

Human dermal fibroblasts (1 x 10<sup>4</sup> cells per well in 24-well plates) were cultured for 24 h in complete medium followed by 48 h in starvation medium. At this time, fresh starvation medium was added in the absence or presence of PDGF-BB (3 - 10 ng/ml), hyaluronan (5 or 25  $\mu$ g/ml), and monoclonal antibodies against the hyaluronan receptor CD44 (100  $\mu$ l Hermes-1 serum-free myeloma culture medium / ml which specifically inhibits the binding of

hyaluronan to the CD44 or 50  $\mu\text{g}$  Hermes-3 IgG / ml, ammonium sulfate precipitate; generously provided by professor Sirpa Jalkanen, Turku, Finland), or combinations thereof, and 16 h later the cells were treated with a 6 h pulse of 0.2  $\mu\text{Ci}$  of [ $^3\text{H}$ ]thymidine per well. Media were then aspirated, cells washed with PBS and incubated with 5% trichloroacetic acid for 20 min at 4°C. Cell layers were washed twice with water followed by lysis in 400  $\mu\text{l}$  of 1 M NaOH for 30 min at room temperature and neutralization with 500  $\mu\text{l}$  of 1 M HCl. The precipitated DNA was then processed for scintillation counting.

## RESULTS

### **PDGF-BB is the predominant stimulator of hyaluronan production in human dermal fibroblast cultures**

Our previous studies revealed that PDGF-BB is a potent stimulator of hyaluronan synthesis in cells of mesenchymal origin, such as fibroblasts and mesothelial cells [20, 33]. However, in order to investigate whether there are differences in the hyaluronan synthesizing capacity of various fibroblast-derived cell lines, including primary fibroblast cultures derived from normal human dermis and from keloid-like dermal scars [34], as well as in a panel of epithelial cells, the PDGF-BB-mediated hyaluronan production by various connective tissue cell types was studied. The analysis revealed that untreated and PDGF-BB-treated 3T3 mouse embryo fibroblasts and human adult lung fibroblasts synthesized about 650 ng and 750 ng hyaluronan per  $1 \times 10^5$  cells and 24 h, respectively, independently of PDGF-BB stimulation. Notably, MEFs, 293 cells and Cos-1 cells synthesized only minute amounts of hyaluronan (Fig. 1). The hyaluronan content in 24 h-conditioned media from subconfluent cultures of human foreskin fibroblasts AG 1518 and AG1523, as well as fibroblasts derived from normal dermis or dermal keloid scars, were increased 2 - 4-fold, when cells were stimulated with PDGF-BB (Fig. 1). Among the cells with an epithelial phenotype, primary human epidermal keratinocytes synthesized hyaluronan in a PDGF-BB-independent manner, consistent with the lack of PDGF receptors on these cells, whereas the synthesis of hyaluronan by the human epithelial cell line HaCat was stimulated by PDGF-BB. Notably, the mammary NMuMG cells did not synthesize any significant amounts of hyaluronan (Fig. 1).

Thus, the hyaluronan synthesizing capacity of fibroblasts derived from various origins, differs upon PDGF-BB stimulation; the primary cultures of human dermal fibroblasts exhibited the highest hyaluronan production in response to PDGF-BB, compared to other cells tested, and were thus chosen for further studies.

We next investigated the effects of other growth factors of importance for the biology of dermis, on hyaluronan synthesis at concentrations found to give maximum effects (data not shown). PDGF-BB stimulated hyaluronan synthesis in human dermal fibroblasts even more efficiently than 10% FBS (Fig. 2A). Epidermal growth factor (EGF) slightly increased the hyaluronan content in the conditioned 24 h media, whereas basic fibroblast growth factor (bFGF) and transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) had no effect. Addition of EGF together with PDGF-BB did not increase hyaluronan production appreciably over that synthesized in response to PDGF-BB alone, whereas addition of bFGF gave a slightly decreased effect. Interestingly, addition of TGF- $\beta$  to PDGF-BB resulted in an about 72% decrease in the amount of hyaluronan compared to stimulation with PDGF-BB alone (Fig. 2A). These data support the notion that PDGF-BB has a major role in hyaluronan biosynthesis in dermis. The stimulatory effects of PDGF-BB were higher in primary subconfluent cultures compared with that of confluent cultures of human dermal fibroblasts (Fig. 2B).

### **PDGF-BB and TGF- $\beta$ 1 affect differentially the enzymes involved in synthesis and degradation of hyaluronan**

As a first step to further elucidate which of the three HAS isoforms accounts for the increased levels of hyaluronan in the conditioned media of dermal fibroblast cultures, in response to PDGF-BB, we determined the mRNA levels of *HAS* genes in non-stimulated and PDGF-BB stimulated cells using real-time PCR. Furthermore, to investigate whether the hyaluronan degradative enzymes also contributed to the modulation of the levels of hyaluronan in the conditioned media, the levels of mRNAs for *HYAL1* and *HYAL2* were also determined. The analysis of non-stimulated and PDGF-BB-stimulated dermal fibroblasts, at 1 h, 4 h and 24 h, revealed that dermal fibroblasts expressed only traces of *HAS1*, *HAS3* and *HYAL1* transcripts. PDGF-BB stimulation of the cells triggered an early and significant induction (after 1 h of stimulation) of mRNAs for *HAS1* (10-fold), *HAS3* (7-fold) and *HYAL1* (4-fold) compared with the corresponding basal transcript levels ( $p < 0.05$ ). Longer treatments of cell cultures with PDGF-BB, led to a decline in the expression levels of *HAS1* and *HAS3*, whereas the *HYAL1* transcript was high even after 4 h of stimulation, followed by a decline at 24 h. Independently of the degree of stimulation, the mRNA levels of *HAS1*, *HAS3* and *HYAL1* were very low (between 0.01% - 0.07%) compared to *GAPDH*. Importantly, dermal fibroblasts exhibited a high basal expression of *HAS2* and *HYAL2* mRNA levels, about 900-fold and 40-fold higher compared to *HYAL1* (1 x sample) (Fig. 3). The already high transcriptional activity of *HAS2* gene in non-stimulated cells, was induced about 3-fold after 4

h of stimulation with PDGF-BB; after longer treatment, the *HAS2* gene expression still possessed transcriptional activity significantly higher compared to control levels (Fig. 3). Notably, the endogenous high transcriptional activity of *HYAL2* did not significantly change from 1 h to 24 h in response to PDGF-BB. Comparing the mRNA levels of the *HAS2* and *HYAL2* isoforms with those of *GAPDH*, revealed that the *HAS2* and *HYAL2* transcript levels were about 36% and 0.6% in PDGF-BB-stimulated cells, respectively, of those of *GAPDH*. Thus, it is likely that the induction of the *HAS2* gene and, to a lesser extent, the *HAS1* and *HAS3* genes, rather than the suppression of *HYAL1* and *HYAL2* genes, accounts for the increased hyaluronan levels in response to PDGF-BB in dermal fibroblast cultures.

We next investigated, using immunoblotting, the expressions of HAS2, HYAL1 and HYAL2 protein in 6 h PDGF-BB-stimulated and quiescent fibroblast cultures (Fig. 4). Bands of approximately 65 kDa (consistent with the size of HAS2) and about 50 kDa (consistent with the size of HYAL2) were seen in lysates of dermal fibroblasts when blots were incubated with polyclonal HAS2 or HYAL2 antibodies, respectively, but not when the antiserum was pre-incubated with a 200-fold excess of the respective peptides used for immunization. Furthermore, a 50 kDa component, consistent with the size of HYAL1 [35, 36], was detected using the 17E9 monoclonal antibodies against HYAL1 [37]. Despite the low amount of *HYAL1* mRNA (Fig. 3), an appreciable amount of HYAL1 protein was expressed. PDGF-BB-stimulated cells expressed more HAS2 protein (Fig. 4A) and synthesized more hyaluronan (Fig. 4D) compared to unstimulated cells, whereas neither the HYAL1 nor the HYAL2 proteins changed significantly (Figs 4B and C). In addition, PDGF-BB-stimulated dermal fibroblasts exhibited similar activity of hyaluronidase(s) present in cell-layer extracts and conditioned media as the non-stimulated cells (Fig. 4E). Thus, PDGF-BB-mediated stimulation of hyaluronan synthesis is due to upregulation of HAS2 expression.

Because treatment of dermal fibroblasts with TGF- $\beta$  suppressed the stimulatory effect of PDGF-BB on hyaluronan production (Fig. 2A), we investigated the effects of TGF- $\beta$  on the expression of HAS2, HYAL1 and 2 as well as on hyaluronidase activity present in cell-layer extracts and conditioned media. As shown in Fig. 5, TGF- $\beta$  stimulation did not have any effect on HAS2 protein expression or hyaluronan amount in 24 h conditioned media, neither did it affect HYAL1 and 2 expressions. Interestingly, however, stimulation with TGF- $\beta$  increased, in a dose-dependent manner, the hyaluronidase activity about 3 - 4-fold in conditioned media and about 2 - 3-fold in cell layer extracts (Fig. 5E). This data suggests that whereas TGF- $\beta$  does not affect the amount of HYAL1 and 2, it is a powerful stimulator of hyaluronidase activity in dermal human fibroblasts.

### **PDGF-BB-induced stimulation of hyaluronan synthesis requires active Erk1/2 and PI3K signaling pathways**

In order to explore which signaling pathways are important for stimulation of hyaluronan biosynthesis in response to PDGF-BB, we used specific inhibitors of downstream signaling molecules at non-cytotoxic concentrations, as determined by the exclusion of trypan blue (data not shown). The PDGF-BB-induced 2.5-fold increase in the hyaluronan synthesis was completely prevented when the dermal fibroblasts were cultured in the presence of the MEK1/2 inhibitor U0126 that inhibits MEK, an activator of the MAP kinase Erk1/2, or in the presence of the PI3-kinase inhibitor LY294002 (Fig. 6A). Notably, addition of the specific Src inhibitor SU6656 and p38 inhibitor SB203580, only slightly suppressed hyaluronan production (less than 20% inhibition), indicating that these signaling pathways does not have a major role in PDGF-BB-induced hyaluronan synthesis. Thus, the powerful stimulatory effect of PDGF-BB on hyaluronan biosynthesis is dependent on activation of PI3-kinase and Erk1/2 signaling pathways.

Further studies on the more downstream signaling molecules involved in PDGF-BB-mediated hyaluronan synthesis revealed an important role of NFκB. This was demonstrated by using the SN50 peptide inhibitor which is cell-membrane permeable and contains the nuclear localization sequence of NFκB and thereby inhibits the translocation of its active complex into the nucleus. PDGF-BB stimulation of hyaluronan synthesis was decreased about 80% by the SN50 peptide. In contrast, the control SN50M peptide, which has mutations in the nuclear localization sequence of NFκB and thus does not prevent translocation of the NFκB active complex into the nucleus, did not significantly inhibit the hyaluronan produced by PDGF-BB stimulation. These observations support the notion that NFκB has a central role in the activation of hyaluronan synthesis.

Also at the transcriptional level, PDGF-BB-induced *HAS2* gene expression was completely prevented if the fibroblasts were cultured in the presence of the MEK inhibitor U0126, or in the presence of the PI3-kinase inhibitor LY294002; the effects of the inhibitors on PDGF-BB-induction of *HAS1*, *HAS3* and *HYAL2* were less apparent (Fig. 7). Furthermore, the levels of mRNAs for *HYAL1* were also suppressed when these inhibitors were added to the cultures. These studies indicate an involvement of the Erk MAP kinase and PI3-kinase signaling pathways in *HAS2* and *HYAL1* transcriptional activities. A four hours stimulation of the cells with 10% FBS led to increases in *HAS1*, *HAS2* and *HAS3* transcripts; the increase in *HAS2* transcriptional activity was similar to that detected after PDGF-BB stimulation.

However, in addition, 10% FBS caused powerful inductions of *HYAL1* and *HYAL2* transcripts (Fig. 7).

### **Inhibition of hyaluronan binding to CD44 inhibits PDGF-BB-mediated proliferation of human dermal fibroblasts**

In order to investigate whether hyaluronan is of importance for the PDGF-BB-stimulated growth stimulation of dermal fibroblasts, we subjected the cells to a [<sup>3</sup>H]thymidine incorporation assay. As shown in Fig. 8A, PDGF-BB induced [<sup>3</sup>H]thymidine incorporation in a dose-dependent manner. When unstimulated or PDGF-BB-stimulated fibroblasts were cultured in the presence of 5 or 25 µg/ml of hyaluronan, an increase in the PDGF-BB-mediated cell growth was observed (Fig. 8B). Interestingly, this growth-promoting effect of hyaluronan on PDGF-BB-stimulated cells was inhibited in the presence of Hermes-1 antibodies that specifically block the binding of hyaluronan to CD44, but not in the presence of Hermes-3 antibodies that does not effect the binding of hyaluronan to CD44. Thus, binding of hyaluronan to CD44 receptor is important for the proliferative effect of PDGF-BB in dermal fibroblasts in culture.

## **DISCUSSION**

In the present study, we show that among various epithelial and fibroblast cells from different origins, the adult human dermal fibroblasts synthesize the highest amounts of hyaluronan. We used primary cultures of dermal fibroblasts for a thorough analysis of the effects of PDGF-BB and TGF-β1 on the mRNA and protein levels of HAS and HYAL isoforms. PDGF-BB potently stimulated hyaluronan synthesis (Figures 1, 2), *HAS2* gene transcriptional activity (Figures 3 and 7), and HAS2 protein induction (Fig. 4A).

Importantly, we found that inhibition of hyaluronan binding to its receptor CD44 prevents PDGF-BB-induced [<sup>3</sup>H]thymidine incorporation, suggesting that induction of hyaluronan is an important part of the mitogenic PDGF-BB response. Interestingly, we recently found that higher concentrations of hyaluronan (100 µg/ml) inhibits PDGF β-receptor activation in a tyrosine phosphatase-dependent mechanism [25]. Thus, hyaluronan appears to affect PDGF stimulation in a biphasic manner; low concentrations of hyaluronan enhances, whereas high concentrations inhibits, PDGF stimulation.

Previous studies revealed that PDGF-BB and TGF-β induce hyaluronan synthesis in cultures of human foreskin fibroblasts in an additive manner [38]. In contrast, we report here

that in human dermal fibroblast cultures TGF- $\beta$  suppresses the PDGF-BB-induced hyaluronan levels (Fig. 2A). Most likely, the stimulatory effect of TGF- $\beta$ 1 on hyaluronidase activity in dermal fibroblasts (Fig. 5E) contributes to the lowering of the hyaluronan levels. Interestingly, the increase in hyaluronidase activity occurred without an increase in the amount of HYAL protein. It is possible that TGF- $\beta$  induces proteolytic activation of HYAL proteins or induces the synthesis of an activation co-factor. Furthermore, TGF- $\beta$ 1 stimulation of normal human mesothelial cell cultures led to suppression of *HAS2* gene expression but induction of *HAS1* transcript [33]. Thus, the differential effects of TGF- $\beta$ 1 on hyaluronan production and degradation is cell-type specific and involves regulation of both hyaluronan synthesizing and degrading enzymes. These differences may have functional implications since hyaluronan fragments have different effects on cells compared to high molecular weight hyaluronan, and e.g. stimulates angiogenesis in a CD44- and chemokine CXCL1-dependent manner [39].

Following activation of the PDGF  $\beta$ -receptor by PDGF-BB, several signaling pathways are activated. Two of the best defined pathways, supporting cell survival and proliferation, are the Erk MAP kinase and PI3 kinase pathways (Fig. 9). Activation of Erk MAP kinase leads to activation of the 90 kDa ribosomal S6 kinases (RSKs), that are responsible for the phosphorylation of several substrates, such as the transcription factor cAMP response element binding protein (CREB) and the transcriptional inhibitor I $\kappa$ B, that upon phosphorylation is targeted for ubiquitination and degradation leading to activation of NF $\kappa$ B and its translocation to the nucleus and binding to specific promoter elements [40]. The PI3 kinase pathway is also important in the PDGF-mediated anti-apoptotic signaling through Akt and the I $\kappa$ B kinase (IKK) leading to active NF $\kappa$ B complex [41]. As shown in Figures 6 and 7, inhibition of either of these pathways using specific inhibitors results in inhibition of both the *HAS2* transcriptional activity and hyaluronan synthesis, to a similar level as for the non-stimulated cells. Notably, the proximal promoter region of *HAS2* gene has putative binding sites for the CREB and NF $\kappa$ B transcription factors [42] (Fig. 9) which are downstream of the Erk MAP kinase and PI3K signaling pathways. Our finding that inhibition of either of the Erk MAP kinase or PI3-kinase pathways is sufficient to inhibit PDGF-BB-induced hyaluronan synthesis, suggests that these pathways are necessary for induction of hyaluronan synthesis in dermal fibroblasts. More recent studies on the *HAS2* promoter have also identified a functional STAT-responsive element [43]; STAT isoforms are also effector molecules downstream of the PDGF  $\beta$ -receptor.

The composition of the extracellular matrix strongly influences the phenotypes of cells [44], and thus has important pathobiological implications. Hyaluronan and hyaluronan-CD44 complexes have been shown to be involved in the progression of inflammation and cancer [45, 46]. Thus, given the many important functions of hyaluronan and its tight regulation in response to growth factors and cytokines released in rapidly remodeling tissues, further studies on the molecular mechanisms that regulate each *HAS* and *HYAL* gene expression in response to external stimuli are needed.



## REFERENCES

- 1 Laurent, T. C. and Fraser, J. R. E. (1992) Hyaluronan. *FASEB J.* **6**, 2397-2404
- 2 Tammi, M. I. and Tammi, R. (1998) Hyaluronan in the epidermis. In <http://www.glycoforum.gr.jp/science/hyaluronan/hyaluronanE.html>
- 3 Prehm, P. (1984) Hyaluronate is synthesized at plasma membranes. *Biochem. J.* **220**, 597-600
- 4 Weigel, P. H., Hascall, V. C. and Tammi, M. (1997) Hyaluronan synthases. *J. Biol. Chem.* **272**, 13997-14000
- 5 Tammi, M. I., Day, A. J. and Turley, E. A. (2002) Hyaluronan and homeostasis: a balancing act. *J. Biol. Chem.* **277**, 4581-4584
- 6 Camenisch, T. D., Spicer, A. P., Brehm-Gibson, T., Biesterfeldt, J., Augustine, M. L., Calabro, A., Jr., Kubalak, S., Klewer, S. E. and McDonald, J. A. (2000) Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. *J Clin Invest* **106**, 349-360
- 7 Chen, W. Y. and Abatangelo, G. (1999) Functions of hyaluronan in wound repair. *Wound Repair Regen* **7**, 79-89
- 8 Li, Y., Rahmanian, M., Widström, C., Lepperdinger, G., Frost, G. I. and Heldin, P. (2000) Irradiation-induced expression of hyaluronan (HA) synthase 2 and hyaluronidase 2 genes in rat lung tissue accompanies active turnover of HA and induction of types I and III collagen gene expression. *Am. J. Respir. Cell Mol. Biol.* **23**, 411-418
- 9 Jacobson, A., Rahmanian, M., Rubin, K. and Heldin, P. (2002) Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. *Int. J. cancer* **102**, 212-219
- 10 Simpson, M. A., Wilson, C. M. and McCarthy, J. B. (2002) Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. *Am J Pathol* **161**, 849-857
- 11 Stern, R. (2003) Devising a pathway for hyaluronan catabolism: are we there yet? *Glycobiology* **13**, 105R-115R
- 12 Ohno, S., Ijuin, C., Doi, T., Yoneno, K. and Tanne, K. (2002) Expression and activity of hyaluronidase in human periodontal ligament fibroblasts. *J Periodontol* **73**, 1331-1337

- 13 El Hajjaji, H., Cole, A. A. and Manicourt, D. H. (2005) Chondrocytes, synoviocytes and dermal fibroblasts all express PH-20, a hyaluronidase active at neutral pH. *Arthritis Res Ther* **7**, R756-768
- 14 Turley, E. A., Noble, P. W. and Bourguignon, L. Y. (2002) Signaling properties of hyaluronan receptors. *J Biol Chem* **277**, 4589-4592
- 15 Day, A. J. and Prestwich, G. D. (2002) Hyaluronan-binding proteins: tying up the giant. *J Biol Chem* **277**, 4585-4588
- 16 Heldin, P. and Pertoft, H. (1993) Synthesis and assembly of the hyaluronan-containing coats around normal human mesothelial cells. *Exp. Cell Res.* **208**, 422-429
- 17 Heldin, P., Suzuki, M., Teder, P. and Pertoft, H. (1995) Chondroitin sulfate proteoglycan modulates the permeability of hyaluronan-containing coats around normal human mesothelial cells. *J. Cell Phys.* **165**, 54-61
- 18 Laurent, T. C., Laurent, U. B. and Fraser, J. R. (1996) The structure and function of hyaluronan: An overview. *Immunol Cell Biol* **74**, A1-7
- 19 Itano, N., Atsumi, F., Sawai, T., Yamada, Y., Miyaishi, O., Senga, T., Hamaguchi, M. and Kimata, K. (2002) Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. *Proc Natl Acad Sci U S A* **99**, 3609-3614
- 20 Heldin, P., Laurent, T. C. and Heldin, C.-H. (1989) Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. *Biochem. J.* **258**, 919-922
- 21 Yu, J., Moon, A. and Kim, H. R. w. (2001) Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. *Biochem Biophys Res Commun* **282**, 697-700
- 22 Stuhlmeier, K. M. and Pallaschek, C. (2004) Differential effect of transforming growth factor beta (TGF-beta) on the genes encoding hyaluronan synthases and utilization of the p38 MAPK pathway in TGF-beta-induced hyaluronan synthase 1 activation. *J Biol Chem* **279**, 8753-8760
- 23 Heldin, C. H. and Westermark, B. (1999) Mechanism of action and in vivo role of platelet-derived growth factor. *Physiol Rev* **79**, 1283-1316
- 24 Woodard, A. S., Garcia-Cardena, G., Leong, M., Madri, J. A., Sessa, W. C. and Languino, L. R. (1998) The synergistic activity of alphavbeta3 integrin and PDGF receptor increases cell migration. *J Cell Sci* **111 (Pt 4)**, 469-478

- 25 Li, L., Heldin, C.-H. and Heldin, P. (2006) Inhibition of PDGF-BB-induced Receptor Activation and Fibroblast Migration by Hyaluronan Activation of CD44. *J. Biol. Chem.* **281**, 26512-26519
- 26 Watanabe, K. and Yamaguchi, Y. (1996) Molecular identification of a putative human hyaluronan synthase. *J. Biol. Chem.* **271**, 22945-22948
- 27 Spicer, A. P., Augustine, M. L. and McDonald, J. A. (1996) Molecular cloning and characterization of a putative mouse hyaluronan synthase. *J. Biol. Chem.* **271**, 23400-23406
- 28 Lepperdinger, G., Strobl, B. and Kreil, G. (1998) HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. *J Biol Chem* **273**, 22466-22470
- 29 Tengblad, A. (1979) Affinity chromatography on immobilized hyaluronate and its application to the isolation of hyaluronate binding proteins from cartilage. *Biochim. Biophys. Acta* **578**, 281-289
- 30 Johansson, S., Hedman, K., Kjellen, L., Christner, J., Vaheri, A. and Hook, M. (1985) Structure and interactions of proteoglycans in the extracellular matrix produced by cultured human fibroblasts. *Biochem J* **232**, 161-168
- 31 Frost, G. I. and Stern, R. (1997) A microtiter-based assay for hyaluronidase activity not requiring specialized reagents. *Anal Biochem* **251**, 263-269
- 32 Lekanne Deprez, R. H., Fijnvandraat, A. C., Ruijter, J. M. and Moorman, A. F. (2002) Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions. *Anal Biochem* **307**, 63-69
- 33 Jacobson, A., Brinck, J., Briskin, M. J., Spicer, A. P. and Heldin, P. (2000) Expression of human hyaluronan synthases in response to external stimuli. *Biochem. J.* **348**, 29-35
- 34 Sundberg, C., Ivarsson, M., Gerdin, B. and Rubin, K. (1996) Pericytes as collagen-producing cells in excessive dermal scarring. *Lab Invest* **74**, 452-466
- 35 Frost, G. I., Mohapatra, G., Wong, T. M., Csoka, A. B., Gray, J. W. and Stern, R. (2000) HYAL1LUC1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. *Oncogene* **19**, 870-877
- 36 Stern, R. and Csoka, A. B. (2000) Mammalian hyaluronidases. [www.glycoforum.gr.jp/science/hyaluronan/HA15/HA15E.html](http://www.glycoforum.gr.jp/science/hyaluronan/HA15/HA15E.html)

- 37 Frost, G. I., Csoka, A. B., Wong, T. and Stern, R. (1997) Purification, cloning, and expression of human plasma hyaluronidase. *Biochem Biophys Res Commun* **236**, 10-15
- 38 Suzuki, M., Asplund, T., Yamashita, H., Heldin, C.-H. and Heldin, P. (1995) Stimulation of hyaluronan biosynthesis by platelet-derived growth factor-BB and transforming growth factor- $\beta$ 1 involves activation of protein kinase C. *Biochem. J.* **307**, 817-821
- 39 Takahashi, Y., Li, L., Kamiryo, M., Asteriou, T., Moustakas, A., Yamashita, H. and Heldin, P. (2005) Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1/GRO1-dependent manner. *J. Biol. Chem.* **280**, 24195-24204
- 40 Shimamura, A., Ballif, B. A., Richards, S. A. and Blenis, J. (2000) Rsk1 mediates a MEK-MAP kinase cell survival signal. *Curr Biol* **10**, 127-135
- 41 Romashkova, J. A. and Makarov, S. S. (1999) NF- $\kappa$ B is a target of AKT in anti-apoptotic PDGF signalling. *Nature* **401**, 86-90
- 42 Monslow, J., Williams, J. D., Norton, N., Guy, C. A., Price, I. K., Coleman, S. L., Williams, N. M., Buckland, P. R., Spicer, A. P., Topley, N., Davies, M. and Bowen, T. (2003) The human hyaluronan synthase genes: genomic structures, proximal promoters and polymorphic microsatellite markers. *Int J Biochem Cell Biol* **35**, 1272-1283
- 43 Saavalainen, K., Pasonen-Seppanen, S., Dunlop, T. W., Tammi, R., Tammi, M. I. and Carlberg, C. (2005) The human hyaluronan synthase 2 gene is a primary retinoic Acid and epidermal growth factor responding gene. *J Biol Chem* **280**, 14636-14644
- 44 Christofori, G. (2003) Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. *Embo J* **22**, 2318-2323
- 45 Cichy, J. and Pure, E. (2003) The liberation of CD44. *J Cell Biol* **161**, 839-843
- 46 Toole, B. P. (2004) Hyaluronan: from extracellular glue to pericellular cue. *Nat Rev Cancer* **4**, 528-539

## FOOTNOTES

Keywords: Hyaluronan synthase, hyaluronidase, growth factors, signal transduction

This work was supported by grants from the Swedish Cancer Society and the Faculty of Medicine at Uppsala University.

The abbreviations used are: HAS, hyaluronan synthase; HYAL, hyaluronidase; PDGF, platelet-derived growth factor; TGF- $\beta$ 1, transforming growth factor- $\beta$ 1; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; PBS, phosphate-buffered saline; FBS, fetal bovine serum.

## FIGURE LEGENDS

### Fig. 1. Effects of PDGF-BB on hyaluronan synthesis by different types of cells

Hyaluronan content in 24 h-conditioned media was determined in cells ( $3 \times 10^4$  cells / well in 12 well plates) stimulated or not by PDGF-BB (50 ng/ml), as described in Materials and Methods. Data shown is a representative one from three separate experiments with similar results. Columns depict the average of duplicate determinations  $\pm$  variation. *Open columns*, control cells; *filled columns*, PDGF-BB-stimulated cells.

### Fig. 2. Stimulation of hyaluronan synthesis by growth factors in cultures of human dermal fibroblasts at different cell densities

(A) Quiescent human dermal fibroblasts ( $3 \times 10^4$  cells per well in 12-well plates) were incubated in the absence (medium containing 0.1% FBS) or presence of 10% FBS, PDGF-BB (50 ng/ml), EGF (10ng/ml), bFGF (5 ng/ml), TGF- $\beta$ 1 (5 ng/ml), or combinations thereof. (B) Subconfluent ( $1 \times 10^4$  cells per well in 12-well plates) or confluent ( $4 \times 10^4$  cells per well in 12-well plates) dermal fibroblast cultures were incubated in starvation medium, or in medium supplemented with 10% FBS or 50 ng/ml of PDGF-BB. *Open columns*, subconfluent cultures; *filled columns*, confluent cultures. The hyaluronan amount in the cell culture media was determined after 24 h. Data shown is from a representative experiment out of two separate experiments performed with similar results. Columns depict the average of duplicate determinations  $\pm$  variation. \* significantly different ( $p < 0.05$ ) from non-stimulated cells.

### Fig. 3. Time course of *HAS* and *HYAL* mRNAs expression in response to PDGF-BB

Quiescent human dermal fibroblasts ( $4 \times 10^5$  cells per 10 cm dish) were incubated in the absence (medium containing 0.1% FBS) or presence of PDGF-BB (50 ng/ml) for 1 h, 4 h and 24 h. The relative expression levels of *HAS* and *HYAL* mRNAs were determined by real-time RT-PCR, as described in Materials and Methods. Columns, means of triplicate determinations  $\pm$  SD. Data shown is a representative experiment out of two separate experiments with similar results. *Open columns*, non-stimulated cells; *gray columns*, PDGF-BB-stimulated cells. \* The transcriptional activity for each PDGF-BB-induced *HAS* or *HYAL* gene is significantly different ( $p < 0.05$ ) from non-stimulated cells.

**Fig. 4. Effects of PDGF-BB on HAS2, HYAL1 and 2 protein expression levels, and activities**

Quiescent dermal fibroblasts ( $4 \times 10^5$  cells per 10 cm plate) were incubated in the absence (medium containing 0.1% FBS) or presence of PDGF-BB (5 – 10 ng/ml) for 6 h followed by lysis as described in Materials and Methods. Cell lysates (40  $\mu$ g per well) were subjected to SDS-PAGE using 10% acrylamide gels followed by transfer to nitrocellulose membrane. The blots were incubated with polyclonal antibodies against HAS2 protein (5  $\mu$ g/ml) (A), or against HYAL2 protein (1: 300 dilution) (B), in the absence or presence of a 200 molar excess of the corresponding blocking peptides, respectively. In panel (C) the membrane was blotted with the monoclonal antibody 17E9 against HYAL1 (2  $\mu$ g/ml). Panels (D) and (E) shows the quantifications of hyaluronan content in conditioned media, as well as Hyals activities in conditioned media (open columns) and cell layers (filled columns), respectively. The data shown are representative of two separate experiments with similar results (A, B, C), and the average of two separate experiments (D, E). *Columns*, means of duplicates  $\pm$  variation.

**Fig. 5. Effects of TGF- $\beta$ 1 on HAS2, HYAL1 and 2 protein expression levels and activities**

Lysates (40  $\mu$ g per well) from quiescent or TGF- $\beta$ 1-stimulated cells were subjected to SDS-PAGE using 10% acrylamide gels followed by transfer to nitrocellulose membrane. The blots were incubated with polyclonal antibodies against HAS2 protein (5  $\mu$ g/ml) (A), against HYAL2 protein (1: 300 dilution) (B), in the absence or presence of a 200 molar excess of the corresponding blocking peptides, or against the monoclonal antibody 17E9 against HYAL1 (2  $\mu$ g/ml) (C). (D) shows the quantifications of hyaluronan content in conditioned media, and (E) hyaluronidase activity in conditioned media (open columns) and cell layers (filled columns), respectively. The data shown are representatives of two separate experiments with similar results (A, B, C), and the average of two separate experiments (D, E). *Bars*, means of duplicates  $\pm$  variation.

**Fig. 6. Effects of inhibitors on hyaluronan synthesis by dermal fibroblasts**

Quiescent dermal fibroblasts ( $3 \times 10^4$  cells per well in 12-well plates) were cultured in the absence (medium containing 0.1% FBS) or presence of PDGF-BB (50 ng/ml), the Src inhibitor SU6656 (2  $\mu$ M), the p38 inhibitor SB203580 (10  $\mu$ M), the MEK1/2 inhibitor U0126 (10  $\mu$ M), the PI3-K inhibitor LY294002 (20  $\mu$ M), the NF $\kappa$ B inhibitor SN50 (16  $\mu$ M) and its control inhibitory peptide SN50M (16  $\mu$ M), and 10% FBS or combinations thereof for 24 h. Hyaluronan content in conditioned media was measured as described in Materials and

Methods. # significantly different ( $p < 0.01$ ) compared to non-stimulated control cells; \* significantly different ( $p < 0.01$ ) from PDGF-BB-stimulated cells. Values are given relative to the stimulation given by 10% FBS  $\pm$  SD. The data is a representative experiment from three separate ones with similar results. *Bars*, means of duplicates  $\pm$  variation.

**Fig. 7. *HAS* and *HYAL* mRNA expression in response to PDGF-BB and inhibitors**

Quiescent dermal fibroblasts ( $4 \times 10^5$  cells per 10 cm dish) were treated with PDGF-BB (50 ng/ml), MEK1/2 inhibitor U0126 (10  $\mu$ M) and PI3 kinase inhibitor LY294002 (20  $\mu$ M), alone or in combinations, for 4 h. The relative expressions levels of *HAS* and *HYAL* mRNAs were determined by real-time PCR, as described in Materials and Methods. *Bars*, means of triplicate determinations  $\pm$  SD. Data shown is from a representative experiment of two separate experiments with similar results. \*  $p < 0.01$  compared to control.

**Fig. 8. PDGF-BB-mediated incorporation of [<sup>3</sup>H]thymidine to fibroblast cultures is promoted by hyaluronan binding to CD44**

Cells ( $1 \times 10^4$  /well in 12-well plates) after a 48 h of starvation, were cultured for an additional 16 h in starvation medium alone or in medium containing PDGF-BB (3-10 ng/ml), hyaluronan (5 or 25  $\mu$ g/ml), Hermes-1 (100  $\mu$ l/ml), Hermes-3 (50  $\mu$ g/ml) or combinations thereof. Then, [<sup>3</sup>H]thymidine was added and the cultures were incubated for 6 h at 37°C, as described in Materials and Methods. In panel (A), PDGF-BB-induced [<sup>3</sup>H]thymidine incorporation in a dose- dependent manner is depicted. The data is a representative experiment out of two performed. In panel (B), hyaluronan addition alone promoted PDGF-BB-induced [<sup>3</sup>H]thymidine incorporation, and, its addition together with Hermes-1 that blocks the binding of hyaluronan to CD44 suppressed PDGF-BB growth promoting capacity. *Open columns*, unstimulated cells; *filled columns*, PDGF-BB-stimulated fibroblasts (3 ng/ml). The data is the average of two separate experiments. *Bars* both in (A) and (B) are means of triplicate determinations  $\pm$  SD.

**Fig. 9.**

Schematic illustration of signaling pathways downstream of the PDGF  $\beta$ -receptor that are involved in *HAS2* gene regulation



**Table 1. Primer sequences and real-time PCR parameters used for the quantification of gene expression in human dermal fibroblasts**

Target gene	Primer sequence	Amplicon (bp)	Tm (°C)	Gene bank accession number
<i>HAS1</i>	For 5' GGAATAACCTCTTGCAGCAGTTTC 3' Rev 5' GCCGGTCATCCCCAAAAG 3'	84	81	U59269
<i>HAS2</i>	For 5' TCGCAACACGTAACGCAAT 3' Rev 5' ACTTCTCTTTTCCACCCCAIT 3'	77	77	U54804
<i>HAS3</i>	For 5' AACAAAGTACGACTCATGGATTTCCT 3' Rev 5'GCCCGCTCCACGTTGA3'	71	83	AF232772
<i>HYAL1</i>	For 5' GATGTCAGTGTCTTCGATGTGGTA 3' Rev 5'GGGAGCTATAGAAAATTGTCATGTCA3'	79	82	U03056
<i>HYAL2</i>	For 5' CTAATGAGGGTTTTGTGAACCAGAATAT 3' Rev 5' GCAGAATCGAAGCGTGGATAC 3'	79	79	AJ000099
<i>GAPDH</i>	For 5' CCCATGTTTCGTCATGGGTGT 3' Rev 5' TGGTCATGAGTCCTCCACGA TA 3'	145	84	NM_002046

\*Tm (melting temperature): the maximum value for dissociation curve which is a useful tool to verify a specific amplicon product.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7








Fig. 8



PDGF-BB									+	+	+	+	+	+	+
Hermes-1				+	+							+	+		
Hermes-3						+	+							+	+
Hyaluronan (µg/ml)	-	5	25	5	25	5	25	-	5	25	5	25	5	25	

Fig. 9

